Report on recent progress of myelodysplastic syndrome in the 54th ASH annual meeting / 白血病·淋巴瘤

ABSTRACT

The myelodysplastic syndromes (MDS) are a group of clonal disorders of the hematopoietic stem/progenitor cells characterized by the presence of ineffective hematopoiesis and an increased risk of transformation to acute myeloid leukemia (AML).In the 54th ASH annual meeting,lots of new discoveries about the molecular mechanisms (such as mutations in ASXL1 and Dido1) behind MDS and the relationship between the mechanisms and the clinical outcomes were introduced.On therapy,novel agents based on the molecular mechanisms occured extending survival.Haematopoietic stem cell transplantation (HSCT) remains the only curative therapy,there' re also many developments in HSCT reported in the meeting.